Image may be NSFW.
Clik here to view.
Brinker Capital Investments LLC raised its position in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) by 351.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 64,671 shares of the company’s stock after buying an additional 50,359 shares during the quarter. Brinker Capital Investments LLC owned about 0.15% of Meridian Bioscience worth $1,698,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Allred Capital Management LLC bought a new position in Meridian Bioscience in the 1st quarter worth approximately $26,000. Optimum Investment Advisors purchased a new stake in shares of Meridian Bioscience in the first quarter valued at $32,000. First Bank & Trust purchased a new stake in shares of Meridian Bioscience during the first quarter worth $38,000. ProShare Advisors LLC purchased a new stake in shares of Meridian Bioscience during the fourth quarter worth $191,000. Finally, LS Investment Advisors LLC acquired a new position in Meridian Bioscience during the fourth quarter worth $216,000. Hedge funds and other institutional investors own 95.55% of the company’s stock.
Shares of NASDAQ:VIVO opened at $20.60 on Wednesday. The company has a market cap of $892.60 million, a P/E ratio of 10.30 and a beta of 0.49. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.30 and a current ratio of 3.74. The company has a 50 day moving average of $20.85. Meridian Bioscience, Inc. has a one year low of $12.98 and a one year high of $30.65.
Meridian Bioscience (NASDAQ:VIVO) last posted its quarterly earnings data on Thursday, May 6th. The company reported $0.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.08. The company had revenue of $85.26 million during the quarter, compared to analysts’ expectations of $87.24 million. Meridian Bioscience had a net margin of 26.62% and a return on equity of 32.03%. As a group, equities analysts predict that Meridian Bioscience, Inc. will post 1.72 earnings per share for the current fiscal year.
VIVO has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Wednesday, April 28th. HC Wainwright cut their price objective on shares of Meridian Bioscience from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, May 10th.
Meridian Bioscience Profile
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H.
See Also: How Do Mutual Funds Work?
Image may be NSFW.
Clik here to view.
